NO954132L - Defective recombinant adenoviruses for tumor gene therapy - Google Patents

Defective recombinant adenoviruses for tumor gene therapy

Info

Publication number
NO954132L
NO954132L NO954132A NO954132A NO954132L NO 954132 L NO954132 L NO 954132L NO 954132 A NO954132 A NO 954132A NO 954132 A NO954132 A NO 954132A NO 954132 L NO954132 L NO 954132L
Authority
NO
Norway
Prior art keywords
gene therapy
defective recombinant
recombinant adenoviruses
tumor gene
defective
Prior art date
Application number
NO954132A
Other languages
Norwegian (no)
Other versions
NO321454B1 (en
NO954132D0 (en
Inventor
Michel Perricaudet
Hedi Haddada
Evelyne May
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO954132L publication Critical patent/NO954132L/en
Publication of NO954132D0 publication Critical patent/NO954132D0/en
Publication of NO321454B1 publication Critical patent/NO321454B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Defective recombinant adenovirus contains a heterologous DNA sequence (I), the expression of which in a target cell contributes to the inhibition of cell division.
NO19954132A 1993-04-22 1995-10-17 Defective, recombinant adenovirus containing a heterologous DNA sequence whose expression in a target cell allows at least partially to inhibit cell division, uses, and pharmaceutical preparation thereof. NO321454B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9304745A FR2704234B1 (en) 1993-04-22 1993-04-22 RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
PCT/FR1994/000421 WO1994024297A1 (en) 1993-04-22 1994-04-15 Defective recombinant adenoviruses for gene therapy of tumours

Publications (3)

Publication Number Publication Date
NO954132L true NO954132L (en) 1995-10-17
NO954132D0 NO954132D0 (en) 1995-10-17
NO321454B1 NO321454B1 (en) 2006-05-15

Family

ID=9446321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19954132A NO321454B1 (en) 1993-04-22 1995-10-17 Defective, recombinant adenovirus containing a heterologous DNA sequence whose expression in a target cell allows at least partially to inhibit cell division, uses, and pharmaceutical preparation thereof.

Country Status (15)

Country Link
EP (2) EP1652931A3 (en)
JP (1) JPH08508879A (en)
AT (1) ATE332386T1 (en)
AU (1) AU696245B2 (en)
DE (1) DE69434781T2 (en)
DK (1) DK0695360T3 (en)
ES (1) ES2264123T3 (en)
FI (1) FI118011B (en)
FR (1) FR2704234B1 (en)
HU (1) HU220346B (en)
NO (1) NO321454B1 (en)
NZ (1) NZ265306A (en)
PT (1) PT695360E (en)
WO (1) WO1994024297A1 (en)
ZA (1) ZA942778B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
FR2717496B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
PT797676E (en) * 1993-10-25 2006-05-31 Canji Inc RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE
FR2717497B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2717495B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP3816518B2 (en) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE IN GENE THERAPY
FR2726285B1 (en) * 1994-10-28 1996-11-29 Centre Nat Rech Scient ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
US7097972B1 (en) 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6015665A (en) * 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
US7807783B1 (en) 1995-04-03 2010-10-05 The Regents Of The University Of Michigan Methods and compositions for regulating FAS-associated apoptosis
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DK0833934T4 (en) 1995-06-15 2012-11-19 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
US6482803B1 (en) 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
FR2790484B1 (en) 1999-03-01 2003-01-03 Michel Marcel Andre Loiselet FERMENTING MIXERS, PROVIDED WITH INNOVATIVE DEVICES IN THE MATERIAL, FOR THE MIXING OF VISCO-ELASTIC PASTA AND THE PRODUCTION OF PASTA LEAVEN
FR2829136B1 (en) 2001-08-29 2006-11-17 Aventis Pharma Sa LIPID DERIVATIVES OF AMINOGLYCOSIDES
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233013T2 (en) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer ADENOVIRUS MEDIATED GENTRANSFER INTO THE GASTROINTESTINAL TRACT
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells

Also Published As

Publication number Publication date
EP0695360A1 (en) 1996-02-07
FR2704234B1 (en) 1995-07-21
JPH08508879A (en) 1996-09-24
PT695360E (en) 2006-09-29
HUT73464A (en) 1996-08-28
NZ265306A (en) 1997-10-24
NO321454B1 (en) 2006-05-15
DE69434781T2 (en) 2007-06-14
EP0695360B1 (en) 2006-07-05
FI118011B (en) 2007-05-31
EP1652931A3 (en) 2006-05-17
WO1994024297A1 (en) 1994-10-27
AU6572194A (en) 1994-11-08
FR2704234A1 (en) 1994-10-28
DK0695360T3 (en) 2006-11-13
HU220346B (en) 2001-12-28
ZA942778B (en) 1995-01-09
FI954966A (en) 1995-10-18
FI954966A0 (en) 1995-10-18
EP1652931A2 (en) 2006-05-03
ES2264123T3 (en) 2006-12-16
AU696245B2 (en) 1998-09-03
NO954132D0 (en) 1995-10-17
DE69434781D1 (en) 2006-08-17
ATE332386T1 (en) 2006-07-15
HU9503035D0 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
NO954132L (en) Defective recombinant adenoviruses for tumor gene therapy
MX9704552A (en) Cells for the production of recombinant adenoviruses.
ATE295739T1 (en) ADENOVIRAL VECTORS INCLUDING A PROSTATE SPECIFIC ANTIGEN (PSA) ßRESPONSE ELEMENTß
BR9407956A (en) Pharmaceutical composition vector of recombinant adenovirus expression and kit to reduce tumor cell proliferation
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
FI951138A (en) Defective adenoviral vectors and their use in gene therapy
EP0063002A3 (en) Radiolabelled peptides derived from crosslinked fibrin for locating thrombi and injectable compositions thereof
BR9609270A (en) Polynucleotide isolated and purified peptide isolated and purified process for detecting the presence of breast cancer in a patient and kit for detecting the presence of breast neoplastic cells in a sample
MX9603002A (en) Method for preparing recombinant adeno-associated viruses (aav), and uses thereof.
ATE295889T1 (en) GENE TRANSCRIPTION AND IONIZING RADIATION: METHODS AND COMPOSITIONS
BR9712942A (en) Method for the production of glycerol, transformed host cell, method for the selection of gene expression, strain pah21 / dh5x of escherichia coli and strain pah21 / dh5x of escherichia coli.
FI962114A (en) Recombinant DNA adenoviruses for cancer gene therapy
ATE424410T1 (en) INTERLEUKIN-19.
AR008847A1 (en) NUCLEIC ACID CONSTRUCTIONS FOR THE REGULATED EXPRESSION OF A TRANSGEN IN A HOSPITAL CELL FOR USE IN PHENIC THERAPY AND GENETIC LAMANIPULATION, AN ISOLATED CELL THAT COMPREHENS THEM AND A PHARMACEUTICAL COMPOSITION
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
MX9601368A (en) Gene therapy for restenosis using an adenoviral vector.
NO910982D0 (en) URATOXYDASE-ACTIVE PROTEIN, RECOMBINANT GENE CODING IT, EXPRESSION VECTOR, MICROORGANISMS AND TRANSFORMER CELLS.
IT8882551A0 (en) FOR SKI BOOTS. HULL STRUCTURE, PARTICULARLY
ATE315094T1 (en) SELF-DELELETING VECTORS FOR CANCER THERAPY
AU582288B2 (en) Vector and method for achieving high level expression in eukaryotic cells
WO1996038556A3 (en) Deltap62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer
IT215363Z2 (en) COATING FOR SHOE HEELS.
HUP0001774A3 (en) Fragments of leptin (ob protein)
HUP0000653A2 (en) Mammalian chemokines

Legal Events

Date Code Title Description
MK1K Patent expired